The PurpleLab^® Resource Center

Headache disorders including migraine are highly prevalent globally, estimated to affect more than 50% of the population at any point and time. In the U.S., migraine patients spend an average of $9,000 more than those without the diagnosis.

Price transparency mandates have introduced an unprecedented volume of data — but turning that data into actionable strategy remains a challenge. Health systems and payers alike are still navigating how to translate pricing insights into stronger contract terms, smarter network expansion and more aligned pricing strategies.

Using non-small cell lung cancer (NSCLC) as an example, PurpleLab and Genentech will explore how to leverage RWD to eliminate blind spots in the patient journey.